Cargando…
The genetics and biology of KRAS in lung cancer
Mutational activation of KRAS is a common oncogenic event in lung cancer and other epithelial cancer types. Efforts to develop therapies that counteract the oncogenic effects of mutant KRAS have been largely unsuccessful, and cancers driven by mutant KRAS remain among the most refractory to availabl...
Autores principales: | Westcott, Peter M. K., To, Minh D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845615/ https://www.ncbi.nlm.nih.gov/pubmed/22776234 http://dx.doi.org/10.5732/cjc.012.10098 |
Ejemplares similares
-
The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
por: Westcott, Peter M. K., et al.
Publicado: (2014) -
Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
por: László, Loretta, et al.
Publicado: (2021) -
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021) -
Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells
por: Chen, Wei-Ching, et al.
Publicado: (2021) -
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
por: Ritu, Kulshrestha, et al.
Publicado: (2021)